Mingjun Li
No. 1 East Jianshe Road
Zhengzhou, 450052, China
Zhengzhou, 450052, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial.
Journal: JAMA
Published: June 17, 2026
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.
Journal: The Lancet. Oncology
Published: March 20, 2026
Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lung cancer: A randomized, double-blind, phase 3 trial.
Journal: Cancer pathogenesis and therapy
Published: November 08, 2024
A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.
Journal: Nature medicine
Published: October 08, 2024
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study.
Journal: The Lancet. Respiratory medicine
Published: February 15, 2024
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK-029A in Treatment-Naive Patients With Advanced NSCLC Harboring EGFR Exon 20 Insertion Mutations: A Phase 1 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 30, 2023
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 13, 2022
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
Journal: BMC medicine
Published: June 09, 2022
CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p.
Journal: Cell cycle (Georgetown, Tex.)
Published: June 07, 2021
Exosomal miR-126 blocks the development of non-small cell lung cancer through the inhibition of ITGA6.
Journal: Cancer cell international
Published: September 06, 2020
Last Updated: 09/26/2026